These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
45. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection: The Azithromycin in Coronary Artery Disease: Elimination of Myocardial Infection with Chlamydia (ACADEMIC) study. Anderson JL; Muhlestein JB; Carlquist J; Allen A; Trehan S; Nielson C; Hall S; Brady J; Egger M; Horne B; Lim T Circulation; 1999 Mar; 99(12):1540-7. PubMed ID: 10096928 [TBL] [Abstract][Full Text] [Related]
47. Relation of antibiotic use to risk of myocardial infarction in the general population. Luchsinger JA; Pablos-Méndez A; Knirsch C; Rabinowitz D; Shea S Am J Cardiol; 2002 Jan; 89(1):18-21. PubMed ID: 11779516 [TBL] [Abstract][Full Text] [Related]
48. Role of IgG-seropositivity to Chlamydia pneumoniae in early thrombotic events after coronary stent placement. da Costa CP; Neumann FJ; Kastrati A; Stallforth I; Schmid M; Joghetai N; Prebeck S; Wagner H; Miethke T Atherosclerosis; 2003 Jan; 166(1):171-6. PubMed ID: 12482564 [TBL] [Abstract][Full Text] [Related]
51. Treatment with the antibiotic roxithromycin in patients with acute non-Q-wave coronary syndromes. The final report of the ROXIS Study. Gurfinkel E; Bozovich G; Beck E; Testa E; Livellara B; Mautner B Eur Heart J; 1999 Jan; 20(2):121-7. PubMed ID: 10099908 [TBL] [Abstract][Full Text] [Related]
54. [Meta-analysis of randomized trials of antimicrobial drugs in the treatment of coronary heart disease]. Skochko OV; Kaĭdashev IP Lik Sprava; 2012; (5):72-86. PubMed ID: 23534274 [TBL] [Abstract][Full Text] [Related]
55. n-3 fatty acids in patients with multiple cardiovascular risk factors. ; Roncaglioni MC; Tombesi M; Avanzini F; Barlera S; Caimi V; Longoni P; Marzona I; Milani V; Silletta MG; Tognoni G; Marchioli R N Engl J Med; 2013 May; 368(19):1800-8. PubMed ID: 23656645 [TBL] [Abstract][Full Text] [Related]
56. Roxithromycin treatment prevents progression of peripheral arterial occlusive disease in Chlamydia pneumoniae seropositive men: a randomized, double-blind, placebo-controlled trial. Wiesli P; Czerwenka W; Meniconi A; Maly FE; Hoffmann U; Vetter W; Schulthess G Circulation; 2002 Jun; 105(22):2646-52. PubMed ID: 12045171 [TBL] [Abstract][Full Text] [Related]
57. Antibiotics for coronary disease: it's time to move on. Conti CR Clin Cardiol; 2004 Dec; 27(12):669. PubMed ID: 15628106 [No Abstract] [Full Text] [Related]
58. Review of evidence for a connection between Chlamydia pneumoniae and atherosclerotic disease. Dugan JP; Feuge RR; Burgess DS Clin Ther; 2002 May; 24(5):719-35. PubMed ID: 12075941 [TBL] [Abstract][Full Text] [Related]
59. [The role of inflammation and infection in acute coronary syndrome]. Blankenberg S; Rupprecht HJ; Bickel C; Hafner G; Meyer J Herz; 2001 Apr; 26 Suppl 1():9-18. PubMed ID: 11349630 [TBL] [Abstract][Full Text] [Related]
60. Antibiotics against Chlamydia pneumoniae and prognosis after acute myocardial infarction. Pilote L; Green L; Joseph L; Richard H; Eisenberg MJ Am Heart J; 2002 Feb; 143(2):294-300. PubMed ID: 11835034 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]